C6orf65 Activators
C6orf65 Activators are a suite of chemical compounds that facilitate the enhancement of the functional activity of C6orf65 through diverse signaling pathways. Forskolin and IBMX work by raising intracellular cAMP, which activates protein kinase A (PKA) and could lead to the phosphorylation of proteins that interact with C6orf65, thereby indirectly enhancing its activity. Similarly, PMA acts as a PKC activator, potentially affecting C6orf65 function by modulating protein-protein interactions through phosphorylation. The bioactive lipid sphingosine-1-phosphate may also play a role in the activation of C6orf65 by binding to its receptors and initiating signaling cascades that influence the protein's activity. Calcium flux modulators such as A23187 and Thapsigargin increase intracellular calcium levels, which could activate calcium-dependent kinases and phosphatases, thereby potentially enhancing C6orf65 activity.
Glucokinase (GK) Activators comprise a diverse array of chemical compounds that enhance the enzyme's activity through various biochemical mechanisms. Substrates and allosteric modulators such as glucose, fructose-1-phosphate, and fructose-6-phosphate directly increase the catalytic efficiency of GK by promoting its affinity for glucose and facilitating its phosphorylating action, a critical step in both glycolysis and glycogen synthesis. Similarly, sorbitol and glucosamine boost GK activity indirectly; sorbitol by increasing intracellular glucose availability through its conversion to fructose, and glucosamine by enhancing the production of fructose-6-phosphate via the hexosamine biosynthesis pathway. Glyceraldehyde further contributes to this activation by increasing the levels of glycolytic intermediates that may allosterically stimulate GK. Additionally, AICAR's activation of AMPK results in the phosphorylation of targets that can modify glucose metabolism in favor of pathways involving GK's phosphorylation activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs), which prevents cAMP degradation. Higher cAMP levels can lead to the activation of PKA that may phosphorylate substrates and modulate C6orf65 function. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator which can phosphorylate proteins that may form complexes with C6orf65, potentially enhancing its activity through altered protein-protein interactions. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is a bioactive lipid that activates sphingosine-1-phosphate receptors, possibly leading to downstream signaling events that enhance C6orf65 activity through altered membrane dynamics or signaling cascades. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, which could activate calcium-dependent protein kinases and phosphatases that modulate C6orf65 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor which leads to increased cytosolic calcium levels, potentially activating calcium-dependent signaling pathways that indirectly enhance C6orf65 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter AKT signaling, which may indirectly influence C6orf65 activity through changes in downstream signaling pathways that affect cellular processes C6orf65 is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor which may alter MAPK/ERK pathway signaling, potentially resulting in changes in protein-protein interactions or phosphorylation states that could enhance C6orf65 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may shift cell signaling towards pathways that enhance the activity of C6orf65, perhaps by reducing competitive signaling or altering substrate availability. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that inhibits several protein kinases, potentially leading to the activation of alternative pathways or proteins that may interact with and enhance C6orf65 activity. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator that can modulate intracellular calcium levels, leading to the activation of calcium-dependent signaling pathways potentially enhancing the activity of C6orf65. | ||||||